1Bukulmez G, Akan T, Ciliv G. Serum adenosine deaminase levels in patients with psoriasis: a prospective case- control study. Eur J Dermatol 2000; 10:274 - 276.
2Erbaqci Z, Erbaqci AB, Koyluoqlu O, et al. Serum adenosine deaminase activity in monitoring disease activity and response to therapy in sever psoriasis. Am Soc Ivest Pathol 2006;49: 101 - 104.
3Johnston A, Gudjonsson JE, Sigmundsdottir H, et al. The anti - inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol 2005;114:154- 163.
4Suglyama H, Gyulai R, Toichi E, et al. Dysfunctional blood and target tissue CD4^+CD25^high regulatory T cells inpsoriasis: mechanism underlying unrestrained pathogenic effector T call proliferation. J Immunol 2005; 174:164- 173.
5Zollner TM, Podda M, Pien C, et al. Proteasome inhibitoion reduces superantigen - mediated T cell activation and the severity of psoriasis in a SCID- hu model. J Clin Invest 2002; 109:671 -679.
6Wellington K, Perry CM. Efalizumab. Am J Clin Dermatol 2005;6: 113- 118.
7Boehncke WH. The alpha- defensins HNP- 1 and HNP- 2 are dominant self- peptides presented by HLA class- Ⅱ molecules in lesional psoriatic skin. Eur J Dermatol 2004; 14:142- 145.
8Brown DW, Baker BS, Ovigne JM, et al. Skin CD4^+ T cells produce interferon - 7 in vitro in response to streptoeoccal antigens in chronic plaque psoriasis. J Invest Dermatlo 2000; 114:576-580.
9Neis MM, PeterS B, Dreuw A, et al. Enhanced expression levels of IL - 31 correlate with IL - 4 and IL - 13 in atopic and allergic contact dermatitis. J Allergy Clin Immunol 2006; 118:930- 937.
3Bata-Csorgo Z, Hammmerberg C, Voorhees JJ,et al.Intralesional T-lymphocyte activation as a mediator of psoriatic epidermal hyperplasia[J].J Invest Dermatol,1995,105(7):89-94.
4Austin LM,Ozawa M,Kikuchi T,et al.The Majority of Epidermal T Cells in Psoriasis Vulgaris Lesions can Produce Type 1 Cytokines, Interferon,Interleukin-2, and Tumor Necrosis Factor, Defining TC1 (Cytotoxic T Lymphocyte) and TH1 Effector Populations:1 a Typ
6Menssen A,Trommler P,Vollmers,et al.Evidence for an antigen-specific celluar immune respons in skin lesions of patients with psoriasis vulgaris[J].J Immunol,1995,155(8):4078-4083.
7Chang JC, Smith LR, Froning KJ,et al.Persistence of T cell clones in psoriatic lesion[J].Arch Dermatol,1997,133(6):703-708.
8Zheng Y,Danilenko D M,Valdez P,et al.Interleukin-22,a T(H)17 cytokine media tes IL-23-induced dermal inflammation and acanthosis[J].Nature,2007,445:648-651.
9Perez-Lorenzo R,Nú(n)ez-Oreza LA,Garma-Quen PM,et al Peripheral blood mononuclear cells proliferation and Th1 /Th2 cytokine production in response to streptococcal M protein in psoriatic patients[J].Int J Dermatol,2006,45:547-553.
10Diluvio L,Vollmer S,Besgen P,et al.Identical TCR beta-chain rearrangements in streptococcal angina and skin lesions of patients with psoriasis vulgaris[J].J Immunol,2006,176:7104-7111.
